Our research focuses on understanding the molecular basis of autoimmune conditions in haematology, particularly immune thrombocytopenia (ITP), a condition leading to premature destruction of platelets.
We combine genetic and genomic analysis of individuals with extreme phenotypes, CRISPR-based in vitro functional validation, and parallel ‘omic' approaches to define novel pathways regulating autoimmunity (eg Afzaku B et al Nat Immunol 2017 18:813-823).
et al., 2021, Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial, Trials, Vol:22, ISSN:1745-6215
et al., 2021, Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia, New England Journal of Medicine, Vol:384, ISSN:0028-4793, Pages:1503-1516
et al., 2020, Identification of occult cerebral microbleeds in adults with immune thrombocytopenia, Blood, Vol:136, ISSN:0006-4971, Pages:2875-2880
et al., 2020, Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials, Pediatric Blood & Cancer, Vol:67, ISSN:1545-5009
et al., 2020, Whole-genome sequencing of a sporadic primary immunodeficiency cohort (vol 583, pg 90, 2020), Nature, Vol:584, ISSN:0028-0836, Pages:E2-E2